NCT06520449 - 68Ga-NTA-476 Imaging in Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

December 12, 2024

Study Completion Date

January 17, 2025

Conditions

Prostate Cancer

Interventions

DRUG

68Ga-NTA-476

The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.

Trial Locations (1)

3051

Melbourne Theranostic Innovation Centre, Melbourne